Clinical Trial

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

Study acronym: ENHANCE
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-14.
Trial Details
NCT Number NCT07542314
Lead Sponsor Sarepta Therapeutics, Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 20 participants
Start Date 2026-07-31
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-26